Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance

IF 1.1 Q4 ALLERGY
Hidehisa Saeki MD, PhD, Hiroyuki Fujita MD, PhD, Katsuhisa Suzuki BSc, Kazuhiko Arima MD, PhD
{"title":"Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance","authors":"Hidehisa Saeki MD, PhD,&nbsp;Hiroyuki Fujita MD, PhD,&nbsp;Katsuhisa Suzuki BSc,&nbsp;Kazuhiko Arima MD, PhD","doi":"10.1002/cia2.12303","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Atopic dermatitis (AD) is a common chronic inflammatory skin disorder in Japan. Dupilumab, a fully human monoclonal antibody, targets a shared subunit of the interleukin (IL)-4 and IL-13 receptors. Post-marketing surveillance of the safety and effectiveness of dupilumab in adult AD patients was conducted in Japan, where the drug is also allowed for use in older adolescents (i.e., ≥15 years), and interim results are reported here.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This observational, multicenter study enrolled Japanese patients with AD who initiated dupilumab between July 2018–June 2020 (UMIN-CTR Trials Registry: UMIN000032807). Baseline demographics, clinical history, medication data and dupilumab safety and effectiveness data were collected.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>By the data cut-off date of March 26, 2021, information from 600 patients has been collected. All the available safety and 1-year effectiveness data are presented. The mean (standard deviation) age was 42.0 (15.9) years, the majority (69.1%) were male, and asthma was present in 12.2%. Adverse drug reactions (ADRs) were observed in 98 patients (16.4%), including conjunctivitis (<i>n</i> = 40; 6.7%), conjunctivitis allergic (<i>n</i> = 30; 5.0%), blepharitis (<i>n</i> = 5; 0.8%), headache and eye pruritus (<i>n</i> = 4; 0.7% each) and eosinophilia (<i>n</i> = 3; 0.5%). Six patients experienced asthma, all of whom had a history of, or concurrent, asthma. Disease severity improved remarkably at 4 months in most patients, which was maintained up to 1 year.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Dupilumab appears to be a safe and effective treatment for patients aged ≥15 years with moderate-to-severe AD in routine clinical practice in Japan. Dupilumab was well tolerated, with no new safety signals and no new-onset asthma.</p>\n </section>\n </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12303","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Atopic dermatitis (AD) is a common chronic inflammatory skin disorder in Japan. Dupilumab, a fully human monoclonal antibody, targets a shared subunit of the interleukin (IL)-4 and IL-13 receptors. Post-marketing surveillance of the safety and effectiveness of dupilumab in adult AD patients was conducted in Japan, where the drug is also allowed for use in older adolescents (i.e., ≥15 years), and interim results are reported here.

Methods

This observational, multicenter study enrolled Japanese patients with AD who initiated dupilumab between July 2018–June 2020 (UMIN-CTR Trials Registry: UMIN000032807). Baseline demographics, clinical history, medication data and dupilumab safety and effectiveness data were collected.

Results

By the data cut-off date of March 26, 2021, information from 600 patients has been collected. All the available safety and 1-year effectiveness data are presented. The mean (standard deviation) age was 42.0 (15.9) years, the majority (69.1%) were male, and asthma was present in 12.2%. Adverse drug reactions (ADRs) were observed in 98 patients (16.4%), including conjunctivitis (n = 40; 6.7%), conjunctivitis allergic (n = 30; 5.0%), blepharitis (n = 5; 0.8%), headache and eye pruritus (n = 4; 0.7% each) and eosinophilia (n = 3; 0.5%). Six patients experienced asthma, all of whom had a history of, or concurrent, asthma. Disease severity improved remarkably at 4 months in most patients, which was maintained up to 1 year.

Conclusion

Dupilumab appears to be a safe and effective treatment for patients aged ≥15 years with moderate-to-severe AD in routine clinical practice in Japan. Dupilumab was well tolerated, with no new safety signals and no new-onset asthma.

Abstract Image

dupilumab在日本治疗特应性皮炎的安全性和有效性:一项上市后监测的1年中期分析
特应性皮炎(AD)是日本常见的慢性炎症性皮肤病。Dupilumab是一种全人源单克隆抗体,靶向白细胞介素(IL) - 4和IL - 13受体的共享亚基。dupilumab在日本对成人AD患者的安全性和有效性进行了上市后监测,该药物也允许用于年龄较大的青少年(即≥15岁),并在此报告了中期结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.60
自引率
10.00%
发文量
69
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信